UBE 将来の成長

Future 基準チェック /16

UBE利益と収益がそれぞれ年間8.3%と5.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に8.2% 8.3%なると予測されています。

主要情報

8.3%

収益成長率

8.3%

EPS成長率

Chemicals 収益成長	16.7%
収益成長率	5.2%
将来の株主資本利益率	8.2%
アナリストカバレッジ	Good
最終更新日	26 Aug 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

OTCPK:UBEO.F - アナリストの将来予測と過去の財務データ ( )JPY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	547,000	36,443	14,967	50,200	7
3/31/2026	526,771	33,214	-25	44,667	7
3/31/2025	511,000	29,100	-46,322	31,630	6
6/30/2024	474,402	30,130	7,472	47,551	N/A
3/31/2024	468,237	28,981	21,988	52,960	N/A
12/31/2023	459,291	14,095	16,402	47,823	N/A
9/30/2023	468,036	2,354	797	30,297	N/A
6/30/2023	487,779	-9,089	-20,254	8,957	N/A
3/31/2023	494,738	-7,006	-8,702	18,127	N/A
12/31/2022	547,036	5,246	-7,547	20,977	N/A
9/30/2022	593,361	14,613	2,289	31,311	N/A
6/30/2022	625,154	25,483	1,911	34,621	N/A
3/31/2022	655,265	24,500	-3,668	32,711	N/A
12/31/2021	651,560	32,062	11,723	44,278	N/A
9/30/2021	640,561	32,210	14,143	48,982	N/A
6/30/2021	624,071	29,022	22,460	62,178	N/A
3/31/2021	613,889	22,936	27,846	66,054	N/A
12/31/2020	608,977	16,773	18,430	60,919	N/A
9/30/2020	612,843	12,458	16,807	61,471	N/A
6/30/2020	638,942	17,104	30,626	71,116	N/A
3/31/2020	667,892	22,976	25,838	68,489	N/A
12/31/2019	687,556	24,830	30,661	75,516	N/A
9/30/2019	716,951	30,937	24,728	65,532	N/A
6/30/2019	726,137	30,116	9,338	52,991	N/A
3/31/2019	730,157	32,499	7,699	50,462	N/A
12/31/2018	728,986	27,855	14,971	51,934	N/A
9/30/2018	716,683	28,251	23,601	64,049	N/A
6/30/2018	705,041	32,028	31,428	67,419	N/A
3/31/2018	695,574	31,680	N/A	73,386	N/A
12/31/2017	683,710	35,783	N/A	67,798	N/A
9/30/2017	662,651	32,860	N/A	58,423	N/A
6/30/2017	638,084	30,584	N/A	55,343	N/A
3/31/2017	616,563	24,185	N/A	53,418	N/A
12/31/2016	599,333	14,955	N/A	60,852	N/A
9/30/2016	599,558	12,504	N/A	66,598	N/A
6/30/2016	618,462	12,901	N/A	65,676	N/A
3/31/2016	641,750	19,111	N/A	68,628	N/A
12/31/2015	650,309	28,748	N/A	72,459	N/A
9/30/2015	657,296	28,317	N/A	70,509	N/A
6/30/2015	654,570	22,232	N/A	70,878	N/A
3/31/2015	641,759	14,649	N/A	62,194	N/A
12/31/2014	647,588	8,133	N/A	47,145	N/A
9/30/2014	647,435	5,991	N/A	40,937	N/A
6/30/2014	645,635	11,698	N/A	36,369	N/A
3/31/2014	650,510	12,623	N/A	37,060	N/A
12/31/2013	638,261	5,312	N/A	37,552	N/A
9/30/2013	626,048	6,481	N/A	42,984	N/A

アナリストによる今後の成長予測

収入対貯蓄率: UBEO.Fの予測収益成長率 (年間8.3% ) は貯蓄率 ( 2.5% ) を上回っています。

収益対市場: UBEO.Fの収益 ( 8.3% ) US市場 ( 15.3% ) よりも低い成長が予測されています。

高成長収益: UBEO.Fの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: UBEO.Fの収益 ( 5.2% ) US市場 ( 8.9% ) よりも低い成長が予測されています。

高い収益成長: UBEO.Fの収益 ( 5.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: UBEO.Fの自己資本利益率は、3年後には低くなると予測されています ( 8.2 %)。

UBE 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

UBE Corporation Revises Earnings Forecast for the First Half of Fiscal Year Ending March 31, 2025

UBE Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

UBE Corporation Revises Earnings Guidance for the First Half Ended September 30, 2022 and Full Year Ending March 31, 2023

Ube Corporation Provides Consolidated Earnings Guidance for the Period Ending September 2022 and March 31, 2023

Recent updates

UBE Corporation Revises Earnings Forecast for the First Half of Fiscal Year Ending March 31, 2025

iSigma Capital Corporation agreed to acquire 84.25% stake in Ube Steel Co.,Ltd from UBE Corporation (TSE:4208).

UBE Corporation to Report First Half, 2025 Results on Nov 07, 2024

UBE Corporation, Annual General Meeting, Jun 26, 2024

UBE Corporation to Report Fiscal Year 2024 Results on May 13, 2024

UBE Corporation Announces Appointment of Hideo Tamada as Director, Effective April 1, 2024

UBE Corporation Announces Dividend for the Year Ended March 31, 2023

UBE Corporation Announces Organizational and Personnel Changes

UBE Corporation to Report Q4, 2023 Results on May 12, 2023

UBE Corporation Announces Resignation of Tetsuro Higashi, Outside Director, Effective January 4, 2023

UBE Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

UBE Corporation Revises Earnings Guidance for the First Half Ended September 30, 2022 and Full Year Ending March 31, 2023

Santen Inc. and UBE Corporation Receives FDA Approval for OMLONTI(R) (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

UBE Corporation Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2023

UBE Corp American Depositary Receipts - Unsponsored to Be Deleted from Other OTC

Ube Corporation Provides Consolidated Earnings Guidance for the Period Ending September 2022 and March 31, 2023

UBE Corporation to Report Q2, 2023 Results on Nov 04, 2022

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘